Walgreens Boots Alliance: Where Things Stand
If you own Walgreens Boots Alliance (NASDAQ: WBA) and were counting on a quick turnaround, it may be time to reassess. Looking at the recent trends and results, the case for keeping capital tied up here has weakened, and directing funds elsewhere could be the more practical move.
Do the Old Walgreens Assumptions Still Hold?
Many investors build a thesis before buying or holding a stock—usually a clear, testable story about growth, stability, and returns. For Walgreens, that story has frayed.
A decade ago, the common view cast Walgreens as a relatively safe choice: a dependable dividend payer with modest, steady share-price gains. The belief was simple and durable—the core pharmacy model would hold up through changing times.
But over the last ten years, total returns have dropped by more than 80%. Free cash flow fell 53% to roughly $327 million. The company also cut its quarterly dividend by 48%, to $0.25 per share—a clear sign of strain rather than strength.
On top of that, a large share of available cash flow has gone to servicing obligations, nearly $27 billion in the last twelve months. When so much is absorbed by debt, there’s less left for expanding the business, rewarding shareholders, or shoring up operations.
It’s worth noting this isn’t a pharmacy-wide collapse. The broader sector has held up better. Competitors, including CVS Health, have maintained a healthier trajectory, preserving share value while raising dividends and free cash flow.
What’s Really Happening in the Stores
There is one bright spot: prescription volume ticked up 1.7% year over year in the most recent fiscal quarter. Even so, Walgreens is under pressure in other parts of the store—non-prescription sales are softer, and reimbursement rates from insurers are tight. The post?pandemic reopening lift has faded, and the day-to-day retail grind has taken its place.
The Risk of Waiting Too Long
Walgreens has looked beyond the pharmacy counter, including moves into primary care. Those efforts aren’t currently bleeding cash, but they also haven’t become a meaningful profit engine.
Delaying harder choices risks extending a damaging debt cycle. If Walgreens turns to selling non?core assets to meet obligations, it could end up smaller and less capable, which in turn can pressure the stock further. That’s the loop to avoid.
Why Selling Might Be the Sensible Call
Could Walgreens recover over the long run? Possibly—especially if primary care eventually contributes real profits. But today’s numbers don’t support that outcome yet, and shareholders don’t have to endure prolonged underperformance while they wait.
Given what’s in front of us, trimming or exiting a position can be the prudent move. If you’re optimistic about a future turnaround, you can always step aside now and come back when there’s clear evidence the story has changed.
Is Walgreens Boots Alliance Worth Buying Right Now?
If you’re weighing a fresh investment in Walgreens Boots Alliance, put the decision in context:
Industry commentary continues to spotlight other growth names that have outpaced Walgreens. Recent analyst attention has highlighted multiple alternatives that aim for sizable long?term gains—and Walgreens Boots Alliance hasn’t been on those shortlists.
The bottom line: Walgreens might eventually find its footing, but it’s wise to weigh the current risk of loss against the uncertain timing of any gains.
Frequently Asked Questions
What’s the short version of Walgreens’ current situation?
The company’s long?time “steady and safe” profile has eroded. Over the past decade, total returns have fallen more than 80%, free cash flow is down 53% to about $327 million, and the quarterly dividend was cut 48% to $0.25. Debt service has taken priority, straining flexibility.
How are the core operations performing?
Prescription volume rose 1.7% year over year in the latest fiscal quarter, but non?prescription sales are under pressure and reimbursement rates remain tight. The reopening boost is gone, and retail conditions are tougher.
Why is debt such a big concern right now?
Much of Walgreens’ cash flow has been directed to servicing obligations—nearly $27 billion in the last twelve months—leaving less room to invest for growth, support the dividend, or stabilize the business. That limits the levers management can pull.
Should I sell my Walgreens shares or wait for a turnaround?
If your original thesis no longer holds, selling can be reasonable. You don’t have to wait through ongoing underperformance; you can exit now and revisit later if results show a clear shift toward recovery.
How does Walgreens compare with peers, and what alternatives exist?
The broader pharmacy sector hasn’t deteriorated to the same degree. Competitors like CVS Health have kept a healthier trajectory, protecting share value while increasing dividends and free cash flow. Industry voices have been emphasizing other growth opportunities over Walgreens at this time.
